NASDAQ: DRTS

Alpha Tau Medical Ltd.

Healthcare | Biotechnology

No licensed closing price on file for DRTS. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-2.15

Alpha Tau Medical Ltd. (NASDAQ: DRTS) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-21 20:17 UTC.

What Alpha Tau Medical Ltd. does

Alpha Tau Medical Ltd., operating under the commercial name Alpha Tau, was founded to develop and advance the Alpha DaRT technology for cancer treatment. The company was established by its Chief Executive Officer and Chairman along with university-based inventors of the underlying technology. Alpha Tau is registered in Israel and maintains executive offices in Jerusalem, with a U.S. service agent located in Massachusetts. The company was created with the mission of translating laboratory-developed technology into clinical applications for cancer patients.

Summarized from Alpha Tau Medical Ltd.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation	6-K 2026-06-25
EPS (TTM)	$-2.15
Debt/equity	3.41

Charts

Charts are in the appInteractive charts for DRTS are available in Oxford Ledge.
Open DRTS in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-08-25

2026-08-25Chief Financial OfficerOption exercise2,871$8.6K
2026-08-25Chief Financial OfficerSale-2,871$43.1K
2026-08-12Chief Financial OfficerOption exercise17,730$52.8K

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

Gem Investment Advisors, LLC1,434,476$18.05M+1161.2%
BOOTHBAY FUND MANAGEMENT, LLC773,481$9.73MNEW
Aquamarine Financial (Cayman) Ltd721,501$9.08M0.0%

View QoQ ownership changes →Full institutional ownership →

Company news

View all →

How Investors Are Reacting To Alpha Tau Medical (DRTS) Expanded Brain Cancer Trial
Yahoo2026-10-21POS
HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $16 Price Target
Benzinga2026-10-20
Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting
Yahoo2026-10-19POS
Alpha Tau Medical Receives FDA Approval For Investigational Device Exemption Supplement To Expand Its U.S. REGAIN Study
Benzinga2026-10-19POS
Alpha Tau to Participate in October Investor Conferences
Yahoo2026-10-05

Questions this page answers

What does Alpha Tau Medical Ltd. do?

Alpha Tau Medical Ltd., operating under the commercial name Alpha Tau, was founded to develop and advance the Alpha DaRT technology for cancer treatment.

When did DRTS last file with the SEC?

Alpha Tau Medical Ltd.'s most recent SEC filing on record is a 6-K filed 2026-06-25. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 20:17 UTC. This page is also available as JSON at /api/data?ticker=DRTS and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for DRTS and 5,000+ tickers.

Create a free account — keep DRTS

For your agent

GET /api/data?ticker=DRTS

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt